# Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).

Source: https://onco.cc/trials/nct06663098/  
OnCo record `nct06663098` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of atezolizumab, carboplatin and etoposide in lung cancer, run by Gruppo Oncologico Italiano di Ricerca Clinica, now recruiting.

## Summary

Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC). is a phase 2, interventional study registered as NCT06663098 by Gruppo Oncologico Italiano di Ricerca Clinica, with a registry enrolment figure of 142 participants, started 2025-01-24 and due to reach its primary completion in 2028-08-30. Interventions recorded: Atezolizumab; Carboplatin; Etoposide. Conditions listed: Extensive Stage Small Cell Lung Cancer (ES-SCLC). Primary outcome: overall survival. Lung eligibility wording from the registry: "Diagnosis of small-cell lung cancer (SCLC) (according to WHO classification 2015) confirmed at pathology (histology or cytology)". Sites: Italy. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: CARRY-ON
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06663098
- Phase: 2
- Setting: Continued PD-L1 Inhibition With Atezolizumab With Rechallenge Chemotherapy in Patients With Sensitive Relapse SCLC Progressing on First-line Platinum-etoposide Chemotherapy and a PD-L1 Inhibitor: CARRY-ON Study-GOIRC-01-2023
- Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica
- Enrolled: 142

## Sources

- ClinicalTrials.gov NCT06663098: https://clinicaltrials.gov/study/NCT06663098

## Connected records

- cancers: [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Etoposide](https://onco.cc/drugs/etoposide/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06663098.json